Download fulltext HTML

https://doi.org/10.18502/wkmj.v65i4.14685

statistics

  • 153 Abstract Views
  • 85 PDF Views
  • 0 HTML Views

authors

  • Raisa A. Aringazina

    Raisa A. Aringazina

    Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
    https://orcid.org/0009-0005-1932-9177
  • Nurgul Abenova

    Nurgul Abenova

    Department of Internal Diseases No. 1, West Kazakhstan Marat Ospanov Medical University, Aktobe, Kazakhstan
    https://orcid.org/0000-0003-0395-9025
  • Sajad Ahmad Bhat

    Sajad Ahmad Bhat

    Department of Biochemistry, International Medical School, Kenzhegali Sagadiyev University of International Business, Almaty, Kazakhstan
    https://orcid.org/0000-0003-0847-9370

Published Date

  • Dec 21, 2023

Subclinical Hypothyroidism and Functional Hemodynamics of the Heart

West Kazakhstan Medical Journal / West Kazakhstan Medical Journal: Volume 65 Issue 4 / Pages 95–100

Abstract

Subclinical hyperthyroidism (SHyper), a laboratory decrease in thyroid-stimulating hormone levels with peripheral thyroid hormone levels within the reference interval, is considered a medical condition, especially its impact on cardiac hemodynamics among young women. To determine the effects of subclinical thyroid dysfunction on hemodynamics in young women. clinical observation included two groups of women: (1) the main group consisted of 30 patients with subclinical hyperthyroidism, which was examined at the Family Medicine Clinic of the West Kazakhstan Marat Ospanov Medical University (Aktobe, Kazakhstan) and (2) the control group consisted of 30 practically healthy women. The groups were comparable in age (30–42), mean age 36.2±7.0 years. Blood pressure (BP) was measured, heart rate (HR) was counted, and thyroid hormones were determined. in the examined patients, clinical symptoms of pathology were not observed; laboratory tests determined a decrease in thyroid-stimulating hormone (TSH) in the main group of patients to 2.48±0.23 mIU/L in comparison with the control group 3.65±1.3 mIU/L, which was significant (p0.05) increase in blood pressure SBP/DBP from 122.34±2.7/78.3±2.7 to 127.8±3.1/83.2±2.1 mmHg and HR from 77.7±1.9 to 82.2±2.6 in 1 minute. A significant (r2 =0.482) interaction was determined between TSH -0.236 mIU/L and HP +20.3 in 1 minute, this could be a predictor of an increase in heart rate greater than the reference value (60–80 per minute), and an increased heart rate is considered a predictor of an increase in blood pressure. Subclinical hyperthyroidism may produce a significant laboratory decrease in TSH, without significant clinical symptoms of increased blood pressure. In conclusion, current observational experience suggests that small decreases in laboratory values of thyroid-stimulating hormone may affect blood pressure and heart rate.

Keywords:

subclinical thyrotoxicosis, thyroid-stimulating hormone, thyroxine, blood pressure

References
[1] Léger J, Carel JC. Diagnosis and management of hyperthyroidism from prenatal life to adolescence. Best Pract Res Clin Endocrinol Metab. 2018;32(4):373–386.

[2] Mooij CF, Cheetham TD, Verburg FA, Eckstein A, Pearce SH, Léger J, et al. 2022 European Thyroid Association Guideline for the management of pediatric Graves’ disease. Eur Thyroid J. 2022 ;11(1):e210073.

[3] Karen Tsai MD, Angela M. Leung, MD, MSc. Subclinical Hyperthyroidism: A Review of the Clinical Literature. Endocr Pract. 27 (2021) 254e260.

[4] Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, et al. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75(3):672–683.

[5] Manolis AA, Manolis TA, Melita H, Manolis AS. Subclinical thyroid dysfunction and cardiovascular consequences: an alarming wake-up call? Trends Cardiovasc Med. 2020;30(2):57–69.

[6] Danzi S, Klein I. Thyroid disease and the cardiovascular system. Endocrinol Metab Clin North Am. 2014;43(2):517–528.

[7] Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59(1):31–50.

[8] Omidi N, Khorgami M, Tajrishi FZ, Seyedhoseinpour A, Pasbakhsh P. The role of thyroid diseases and their medications in cardiovascular disorders: A review of theliterature. Curr Cardiol Rev. 2020;16(2):103–116.

[9] Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction and blood pressure: a community-based study. Clin Endocrinol (Oxf). 2006;65(4):486–491.

[10] Kaminski G, Makowski K, Michałkiewicz D, Kowal J, Ruchala M, Szczepanek E, et al. The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. Thyroid. 2012;22(5):454–460.

[11] Goichot B, Caron P, Landron F, Bouée S. Clinical presentation of hyperthyroidism in a large representative sample of outpatients in France: relationships with age, aetiology and hormonal parameters. Clin Endocrinol. 2016;84(3):445–451.

[12] Völzke H, Ittermann T, Schmidt CO, Dörr M, John U, Wallaschofski H, et al. Subclinical hyperthyroidism and blood pressure in a population-based prospective cohort study. Eur J Endocrinol. 2009;161(4):615–621.

[13] Brusseau V, Tauveron I, Bagheri R, Ugbolue UC, Magnon V, Bouillon-Minois JB, et al. Heart Rate Variability in Hyperthyroidism: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022;19(6):3606.

[14] Vidili G, Delitala A, Manetti R. Subclinical hyperthyroidism: The cardiovascular point of view. Eur Rev Med Pharmacol Sci. 2021;25(8):3264–3271.